Company intelligence / Profile preview

Tridek-One

Ownership: Private
Development stage: Preclinical

Overview

Developing first-in-class CD31 agonist modalities to restore immune balance. Currently in discovery and preclinical stages, working to identify development candidates against autoimmune diseases and conduct IND-enabling studies.

Therapeutic areas: Immunology
Modalities: CD31 agonistspeptides
Industry: Biotech

Drug pipeline

5 assets

Tridek-One anti-CD31/ITAM bispecific antibody

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tridek-One.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tridek-One.

Explore the full profile